U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07866118) titled 'Thymalfasin for Immune Recovery in Adults With Sepsis' on Oct. 04.
Brief Summary: Sepsis is a life-threatening illness caused by an abnormal response to infection. Some people with sepsis have reduced immune function, which may make recovery more difficult. This study will examine whether adding thymalfasin, also called thymosin alpha-1, to usual sepsis care improves recovery of immune function.
The study will enroll 60 adults with sepsis and evidence of reduced immune function at Zhongshan Hospital, Fudan University. Participants will be assigned by chance to one of two groups. Thirty participants will receive usual care plus a 1.6...